Randomised controlled field study to evaluate the efficacy and clinical safety of a single 8 mg/kg injectable dose of marbofloxacin compared with one or two doses of 7.5 mg/kg injectable enrofloxacin for the treatment of Actinobacillus pleuropneumoniae infections in growing-fattening pigs in Europe

Grandemange, Erik; Perrin, Pierre-Alexandre; Cvejic, Dejean; Haas, Miriam; Rowan, Tim; Hellmann, Klaus

doi:10.1186/s40813-017-0057-2

Table 4 Clinical efficacy and safety results for marbofloxacin and enrofloxacin in the treatment of APP associated respiratory disease in fattening pigs

From: Randomised controlled field study to evaluate the efficacy and clinical safety of a single 8 mg/kg injectable dose of marbofloxacin compared with one or two doses of 7.5 mg/kg injectable enrofloxacin for the treatment of Actinobacillus pleuropneumoniae infections in growing-fattening pigs in Europe

		Marbofloxacin				Enrofloxacin				CI of treatment difference
		Absent	Mild	Moderate	Severe	Absent	Mild	Moderate	Severe	CI of treatment difference
Respiratory scores % [n]^a	Day 0	0.0 [0]	0.0 [0]	94.2 [114]	5.8 [7]	0.0 [0]	0.0 [0]	89.8 [106]	10.2 [12]
	Day 2	43.0 [52]	53.7 [65]	2.5 [3]	0.8 [1]	46.2 [54]	49.6 [58]	4.3 [5]	0.0 [0]
	Day 3	68.6 [83]	28.1 [34]	3.3 [4]	0 [0]	65.8 [77]	32.5 [38]	1.7 [2]	0 [0]
	Day 7	94.2 [113]	5.8 [7]	0.0 [0]	0.0 [0]	93.2 [109]	6.8 [8]	0.0 [0]	0.0 [0]
	Day 21	94.7 [108]	3.5 [4]	1.8 [2]	0.0 [0]	95.7 [110]	4.3 [5]	0.0 [0]	0.0 [0]
Depression scores % [n]^a	Day 0	0.0 [0]	89.3 [108]	9.9 [12]	0.8 [1]	0.0 [0]	90.7 [107]	9.3 [11]	0.0 [0]
	Day 2	59.5 [72]	38.0 [46]	2.5 [3]	0.0 [0]	59.8 [70]	40.2 [47]	0.0 [0]	0.0 [0]
	Day 3	80.2 [97]	18.2 [22]	1.7 [2]	0 [0]	80.3 [94]	19.7 [23]	0 [0]	0 [0]
	Day 7	90.8 [109]	9.2 [11]	0.0 [0]	0.0 [0]	92.3 [108]	7.7 [9]	0.0 [0]	0.0 [0]
	Day 21	97.4 [111]	2.6 [3]	0.0 [0]	0.0 [0]	97.4 [112]	2.6 [3]	0.0 [0]	0.0 [0]
Rectal temperatures °C	Day 0	40.6 (0.41) [121]				40.6 (0.40) [118]
	Day 2	39.6 (0.42) [121]				39.7 (0.36) [117]				−0.05; 0.15
	Day 3	39.6 (0.49) [121]				39.6 (0.56) [117]				−0.016; 0.11
	Day 7	39.4 (0.52) [120]				39.4 (0.51) [117]				−0.12; 0.14
	Day 21	39.4 (0.43) [114]				39.5 (0.42) [115]				0.01; 0.23
Retreatment % animals^b	Day 2	n/a				17.8 [21]
Clinical cure % animals^b	Day 7	81.8 [99]				81.4 [96]				−9.37; 10.29
	Day 21	84.2 [101]				82.2 [97]				−7.54; 11.47
SRD removals & mortalities %^b	Days 0–21	5.0 [6]				2.5 [3]				−7.22; 2.38
SRD relapses % animals^b	Days 8–21	0.0 [0]				1.0 [1]				−0.99; 3.07
Adverse events % animals (CI)^c		4.1 [5]				6.7 [8]				−3.1; 8.3
Injection site reactions % animals^c		2.4 [3]				1.6 [2]
Concurrent disorders % animals^c		0.0^d [0]				7.5^e [9]
Live weight gain kg	Days 0–21	19.81 (5.06) [114]				20.05 (7.03) [115]				−0.026; 0.109
No. animals: Intention to treat^c	Day 0	122				120
No. animals: Per protocol^b	Day 7	121				118

Results are for the overall study which included 4 farms and are shown as mean (standard deviation) unless indicated otherwise; CI confidence interval
^aRefer to Clinical examinations for detailed description of individual scores. [n] number of animals
^bIndicated efficacy data percentages are based on per protocol populations. Note that percentages for respiratory and depression scores, and rectal temperatures are based on numbers of animals in a treatment group on a given day, [n]
^cIndicated safety data percentages are based on intention to treat populations. There were no suspected adverse drug reactions
^d,evalues in a row are significantly different. n/a Not applicable
Animals euthanised prior to study for diagnostic purposes are excluded from each of the populations

Back to article page

ISSN: 2055-5660

Contact us

Submission enquiries: journalsubmissions@springernature.com

Porcine Health Management

Contact us